Sunil Nagpal, MD
Hematology & Oncology · Kalamazoo, MINPI 1194734640
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,035 of the $6,193 with a category attached, or 65.2%. 44 manufacturers reported payments, led by Tosoh Bioscience, Inc. at 26.4% of the total.
Across 156 payments — averaging $39.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$2K
- Novartis$534
- Astellas Pharma US Inc$501
- Ipsen Biopharmaceuticals, Inc$469
- Tempus AI, Inc$367
- Merck$252
- plus $2K from 38 others
Across 67 payments — averaging $2846.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$84K
- Genentech, Inc.$71K
- Bristol Myers Squibb$19K
- Pfizer$9K
- Astellas Pharma Global Development$4K
- Merck$4K
- plus $206 from 2 others
What the payments were for
- Food & beverage$4,03565%
- Education$5268%
- Gifts$1,63226%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CORT, ST AIA-PACK$1,088
- CORTISOL, AIA-PACK Sample Diluting Sol$1,088
- ACTH, ST AIA-PACK$1,088
- CORTISOL, AIA-PACK Calibrator Set$544
- ACTH, AIA-PACK CALIBRATOR SET$544
- ACTH, ST AIA-PACK SDS$544
- Wash Concentrate, AIA-PACK$544
- NOZZLE ASSY, 360$544
- ONIVYDE$211
- SIR-Spheres Microspheres$193
- SOMATULINE DEPOT$125
- XT CDX$116
- JEVTANA$105
How this compares
$6,193 in reported general payments places this provider in the 70th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 99 | $1,548,841 |
| JakafiRuxolitinib Phosphate | 24 | $402,797 |
| ImbruvicaIbrutinib | 19 | $322,271 |
| XtandiEnzalutamide | 24 | $300,527 |
| Lenalidomide | 21 | $278,658 |
| VerzenioAbemaciclib | 20 | $213,049 |
| RevlimidLenalidomide | 11 | $182,440 |
| BrukinsaZanubrutinib | 12 | $179,331 |
| Abiraterone Acetate | 85 | $123,761 |
| EliquisApixaban | 75 | $57,429 |
| Anastrozole | 725 | $25,464 |
| Exemestane | 112 | $20,285 |
| Letrozole | 266 | $8,761 |
| XareltoRivaroxaban | 15 | $8,372 |
| Tamoxifen Citrate | 104 | $3,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $250 | $1,606,270174 claims |
| Incyte CorporationJakafi | $239 | $402,79724 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $191 | $322,27119 claims |
| Astellas Pharma US IncXtandi | $501 | $300,52724 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $58 | $213,25133 claims |
| Bristol Myers SquibbRevlimid | $35 | $182,44011 claims |
| Beigene USA, Inc.Brukinsa | $151 | $179,33112 claims |
| Johnson & JohnsonXarelto | $64 | $8,37215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Kalamazoo
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.